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EDITORIAL
Glomerular epithelial cell arachidonate metabolism in
Shiga toxin hemolytic uremic syndrome
The infectious disease, shiga toxin–induced hemolytic Stx HUS [9]. An uncontrolled case series of 22 adults
uremic syndrome (Stx HUS), differs fundamentally from with “HUS/TTP” treated during the Lanarkshire E. coli
other conditions or syndromes classified as thrombotic 0157:H7 outbreak concluded that therapeutic plasma ex-
microangiopathies (TMA). Stx HUS occurs in all age change is “a promising treatment” and that a prospective
groups; therefore, “childhood HUS” does not accurately clinical trial that withholds this treatment option “would
distinguish Stx HUS from other forms of TMA. Similarly, be hard to justify” [9]. This study was severely limited
“epidemic HUS” is misleading because Stx HUS occurs due to confounding by indication. That is, the decision
sporadically and in epidemics. Finally, the assertion that not to provide the treatment to a subset of patients was
adult-onset HUS cannot be differentiated from throm- likely highly correlated with disease severity. Specifi-
botic thrombocytopenic purpura (TTP) [1] is unproved. cally, the patients who did not receive plasma exchange
Such inconsistencies and confusion over nomenclature either died before it could be initiated, or had a contra-
for TMA have hampered clinical studies of Stx HUS [2]. indication to the treatment. The investigators also re-
Therefore, as has been stressed previously [3], any ferred to historical controls and compared their Scottish
patient presenting with bloody diarrhea followed by acute results with those reported in significantly older patients
renal, hematologic, and variable involvement of the cen- years earlier in Canada. Therefore, there is still no evi-
tral nervous system, pancreas, or liver has HUS, regard- dence of a beneficial effect of plasma exchange in chil-
less of age of presentation. Most patients with Stx HUS dren or adults with Stx HUS.
have an antecedent infection with shigatoxin-producing This background concerning treatment is made be-
enteropathogenic Escherichia coli. Alterations in prosta- cause initially the use of fresh-frozen plasma and plasma
cyclin activity in HUS were reported in 1978, prior to exchange was based mainly on the results of studies of
identification of the infectious etiology of Stx HUS [4]. eicosinoids. There are many reported abnormalities in
These observations resulted in case reports and case the eicosanoids, von Willibrand factors (vWf), and cyto-
series of treatment with plasma exchange or infusions kine levels of patients with TMA but blurring of the
of fresh-frozen plasma. Unfortunately, the persistent fail- distinction between HUS and TTP muddles their inter-
ure to distinguish Stx HUS from TTP and from other pretation. More clearly, TTP is associated with abnor-
forms of TMA resulted in confusing and contradictory malities of vWf-cleaving protease activity. In acute TTP,
conclusions not only regarding the pathogenesis but also plasma exchange is indicated because the deficiency is
the results of treatment for children and especially adults due to IgG inhibitory antibodies against the protease
with Stx HUS [5, 6]. There are currently no data to sup- [10], whereas in familial TTP there is a constitutional
port the use of plasma exchange or fresh-frozen plasma deficiency of protease activity [11]. Importantly, neither
infusion in the treatment of Stx HUS. A randomized, of these changes is found in Stx HUS [12].
controlled clinical trial of fresh-frozen plasma infusions The results of studies of prostaglandin metabolism in
in children demonstrated no impact on clinical outcome HUS are confusing [13]. Despite this caveat, the new
[7]. Importantly, a retrospective cohort study of adults observations of Schmid and Kohan in this issue of Kidney
treated with plasma exchange for HUS-TTP revealed International are interesting [14]. They describe the ef-
substantial morbidity and mortality associated with cath- fects of shigatoxin and lipopolysaccharide (LPS) on eico-
eter placement and plasma exchange [8]. Despite the sanoid production and arachidonic acid (AA) release by
lack of evidence for a therapeutic benefit of plasma ex- human glomerular epithelial cells (GEC) [14]. Shiga-
change in Stx HUS and its recognized complications, toxin increases AA release and prostaglandin I2 (PGI2)
investigators continue to advocate plasma exchange for and thromboxane A2 (TxA2) production by GEC in a
dose- and time-dependent manner. Adding LPS potenti-
ates this effect. That these processes are associated with
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increased phospholipase A (PLA) mRNA and proteinnic purpura, plasma exchange, fresh-frozen plasma, human glomerular
epithelial cells. levels suggests that shigatoxin induces PLA gene tran-
scriptioin, which likely contributes to the increased AA 2001 by the International Society of Nephrology
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